Bisacodyl Carcinogenicity Short-Term Study Results Expected Later This Year
This article was originally published in The Tan Sheet
Executive Summary
Results of a 26-week mouse carcinogenicity study on the OTC laxative ingredient bisacodyl are expected to be forwarded to FDA later this year by the Consumer Healthcare Products Association Bisacodyl Task Group. The study in TSG-p53 mice is under way.